Analysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rapid Micro Biosystems (RPID – Research Report), COMPASS Pathways (CMPS – Research Report) and Harrow Health (HROW – Research Report) with bullish sentiments.

Rapid Micro Biosystems (RPID)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Rapid Micro Biosystems on May 8 and set a price target of $8.00. The company’s shares closed last Friday at $0.80, close to its 52-week low of $0.74.

According to TipRanks.com, Arias is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.8% and a 40.0% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Guardant Health, and Mettler-Toledo.

Currently, the analyst consensus on Rapid Micro Biosystems is a Moderate Buy with an average price target of $8.00.

See the top stocks recommended by analysts >>

COMPASS Pathways (CMPS)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways today and set a price target of $120.00. The company’s shares closed last Friday at $8.12.

According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -11.7% and a 29.6% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, Longboard Pharmaceuticals, and Arrowhead Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for COMPASS Pathways with a $45.00 average price target, implying a 412.5% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $50.00 price target.

Harrow Health (HROW)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Harrow Health, with a price target of $26.00. The company’s shares closed last Friday at $10.83, close to its 52-week low of $7.60.

According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -20.4% and a 23.1% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Cognition Therapeutics, and Denali Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Harrow Health with a $23.33 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RPID:

• Rapid Micro Biosystems Grapples with Soaring ESG Compliance Demands: A Financial Health Alert
• Rapid Micro Biosystems reports Q1 EPS (31c), consensus (29c)
• Rapid Micro Biosystems Reports First Quarter 2024 Financial Results
• Is RPID a Buy, Before Earnings?
• Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024